Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
McKesson
Colorcon
McKinsey
AstraZeneca

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Gantenerumab

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Gantenerumab: Patents, clinical trial progress, indications

Gantenerumab is an investigational drug.

There have been 12 clinical trials for Gantenerumab. The most recent clinical trial was a Phase 1 trial, which was initiated on June 6th 2018.

The most common disease conditions in clinical trials are Alzheimer Disease, Dementia, and [disabled in preview]. The leading clinical trial sponsors are Hoffmann-La Roche, Alzheimer's Association, and Accelerating Medicines Partnership (AMP).

There are three US patents protecting this investigational drug and twenty-three international patents.

Recent Clinical Trials for Gantenerumab
TitleSponsorPhase
Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)Hoffmann-La RochePhase 3
Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)Hoffmann-La RochePhase 3
Relative Bioavailability of Gantenerumab Produced by G4 Process Versus G3 Process Following Subcutaneous (SC) Injection in Healthy ParticipantsHoffmann-La RochePhase 1

See all Gantenerumab clinical trials

Clinical Trial Summary for Gantenerumab

Top disease conditions for Gantenerumab
Top clinical trial sponsors for Gantenerumab

See all Gantenerumab clinical trials

US Patents for Gantenerumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Gantenerumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Gantenerumab   Start Trial Treatment of tauopathies Intellect Neurosciences Inc. (New York, NY)   Start Trial
Gantenerumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
McKinsey
Mallinckrodt
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.